| The Significance of E-cadherin As we close Breast Cancer Awareness Month, it’s crucial to shine a light on key markers that play pivotal roles in our understanding of this disease. One such molecule is the E-cadherin mouse antibody. Here’s a quick overview:E-cadherin is a transmembrane glycoprotein, essential for epithelial cell-cell adhesion.Its loss can lead to the disruption of cell clusters, posing potential threats.Intriguingly, E-cadherin might function as a tumor suppressor protein.A growing body of literature suggests that the loss of E-cadherin is linked with metastasis and a negative prognosis in invasive breast cancer.E-cadherin can potentially help in distinguishing between ductal and lobular neoplasms of the breast.Interestingly, the significance of E-cadherin isn’t limited to breast cancer. Research has indicated its role as a potential independent predictor of disease progression in bladder cancer too. Let’s continue our collective efforts in research, awareness, and support to better understand, prevent, and treat breast cancer. Knowledge is our best weapon. 💪🎀 Cellular Localization: Cytoplasmic/membrane Control: Breast cancer Application: IHC-P (FFPE) Format: Concentrate, Predilute |
| GATA-3 in control GATA-3 (GATA binding protein 3) is a member of the GATA family of transcription factors. This 50 kDa nuclear protein regulates the development and subsequent maintenance of multiple tissues. Studies have shown that GATA-3 orchestrates gene expression profiles during embryogenesis of a variety of human tissues, including hematopoietic cells, skin, kidney, mammary gland, and the central nervous system. Among several other roles, GATA-3 has been identified as a key player of luminal cell differentiation in the mammary gland. GATA-3 appears to control a set of genes involved in the differentiation and proliferation of breast cancer. GATA-3 has also been shown to be a novel marker for bladder cancer. Cellular Localization: Nuclear Control: Bladder cancer, breast cancer Application: IHC-P (FFPE) Format: Concentrate, Predilute  Breast cancer stained with GATA-3 antibody |
Programmed death ligand 1 (PD-L1, also known as CD274) inhibits tumor-reactive T-cells via binding to the programmed death-1 (PD-1) receptor, rendering tumor cells resistant to CD8+ T cell-mediated lysis. Studies have shown that the inhibitory receptor PD-1 is expressed on tumor-infiltrating lymphocytes (TIL) while PD-L1 is expressed on tumor cells. Assessment of PD-L1 expression in combination with CD8+ TIL density may be a useful predictive metric in multiple cancers, including stage III NSCLC, hormone receptor negative breast cancer and sentinel lymph node melanoma. Clinical trials utilizing humanized chimeric antibodies that block inhibitory checkpoints, such as anti-PD-1 and anti-PD-L1, have demonstrated delayed tumor growth and increased survival. While identification of PD-L1 overexpression by IHC is not yet standardized, it has become increasingly important to identify these tumors, as a directed therapy may improve clinical outcomes in these patients. In cutaneous melanoma, the targeting of PD-1/PD-L1 has provided meaningful clinical benefit for patients in just the past 5-10 years. The use of IHC for protein identification, along with novel therapies, such as checkpoint inhibitors and vaccines, are generating new options for the treatment of cancer patients. The PD-L1 [CAL10] clone does not cross react with PD-L2. Cellular Localization: Membranous/cytoplasmic Control: Lung adenocarcinoma, tonsil Application: IHC-P (FFPE) Format: Concentrate, Predilute |
| The above antibodies are only a small selection of our extensive antibody portfolio. Please feel free to contact us with your questions. Whether there is a target that is not functioning optimally, or your preferred item is being discontinued, or if you need to reconsider some products for budget reasons, reach out to us and we will do what we can to find the best solution for your challenges. |